Table 1 Any-grade treatment-related and TEAEs, regardless of causality
From: The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Event | Overall population (n = 68) |
|---|---|
Any-grade TRAE (5% or over) | 53 (77.9%) |
ECG QT prolonged | 36 (52.9%) |
Nausea | 18 (26.5%) |
Differentiation syndrome | 11 (16.2%) |
Vomiting | 11 (16.2%) |
Diarrhoea | 7 (10.3%) |
Decreased appetite | 5 (7.4%) |
Dysgeusia | 5 (7.4%) |
Any-grade TEAE (20% or over) | 67 (98.5%) |
ECG QT prolonged | 38 (55.9%) |
Nausea | 34 (50.0%) |
Vomiting | 27 (39.7%) |
Febrile neutropenia | 21 (30.9%) |
Diarrhoea | 20 (29.4%) |
Fatigue | 18 (26.5%) |
ALT increased | 17 (25.0%) |
Headache | 16 (23.5%) |
Hyperphosphataemia | 16 (23.5%) |
Hypokalaemia | 15 (22.1%) |
Hyponatraemia | 15 (22.1%) |
Thrombocytopenia | 15 (22.1%) |
Epistaxis | 14 (20.6%) |
Peripheral oedema | 14 (20.6%) |
